About this trial
This clinical trial, led by Dr. Enitan A. Sogbesan at the Hamilton Regional Eye Clinic, St. Joseph's Healthcare Hamilton, aims to compare the efficacy and safety of non-steroidal anti-inflammatory drug (NSAID) ketorolac alone versus a combination of ketorolac and the corticosteroid fluorometholone, and a control group receiving no postoperative treatment. The trial will evaluate these treatment strategies following Selective Laser Trabeculoplasty (SLT) in patients with open-angle glaucoma. The primary objective is to determine the most effective postoperative management strategy to reduce inflammation, improve patient comfort, and control intraocular pressure (IOP). Participants will be randomly assigned to one of the three groups, with follow-up visits scheduled at 1 hour, 1 week, 1 month, 3 months, 6 months, and 1 year post-SLT. The study's findings aim to guide clinicians in optimizing postoperative care for better patient outcomes.
Eligibility criteria
Qualifiers
Adults aged 18 years and older.
Diagnosed with open-angle glaucoma.
Intraocular pressure (IOP) greater than 16 mmHg on at least two consecutive occasions separated by one month.
Visual acuity of 20/200 or better in at least one eye.
Disqualifiers
Patients with any other ocular disorders or surgeries within the last six months.
Allergy or intolerance to ketorolac or fluorometholone.
Previous use of systemic ketorolac or fluorometholone in the past month.
Pregnancy or breastfeeding.
Trial design
Treatments tested in this trial
- Ketorolac 0.5% Eye Drops
- Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops